First, we showed that a combined therapy utilizing the novel mTOR/AKT inhibitor FC85 and the MDM2/p53 inhibitor ISA27 produced a synergistic effect on the inhibition of GBM cell viability as well as on the reactivation of p53 pathway. Here, MTOR is linked to glioblastoma.